HC Wainwright Issues Pessimistic Forecast for BCYC Earnings

Key Points

• HC Wainwright has revised its Q3 2025 earnings estimate for Bicycle Therapeutics PLC to ($1.17) EPS, down from the previous estimate of ($1.07), indicating a more negative outlook for the company's financial performance.
• Bicycle Therapeutics reported a miss in its latest quarterly earnings, with a loss of ($1.14) EPS compared to the consensus estimate of ($0.95), and revenue of $2.90 million versus expectations of $9.43 million.
• Target prices for Bicycle Therapeutics shared by different analysts have been significantly lowered, with Barclays reducing its target from $40.00 to $15.00, reflecting a cautious sentiment regarding the company's future performance.

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Free Report) - Analysts at HC Wainwright cut their Q3 2025 EPS estimates for Bicycle Therapeutics in a note issued to investors on Monday, August 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($1.17) for the quarter, down from their previous forecast of ($1.07). The consensus estimate for Bicycle Therapeutics' current full-year earnings is ($3.06) per share. HC Wainwright also issued estimates for Bicycle Therapeutics' Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($4.29) EPS, FY2026 earnings at ($4.26) EPS, FY2027 earnings at ($3.32) EPS, FY2028 earnings at ($1.13) EPS and FY2029 earnings at $1.67 EPS.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its earnings results on Friday, August 8th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.19). The firm had revenue of $2.90 million during the quarter, compared to analysts' expectations of $9.43 million. Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%.

Other research analysts also recently issued reports about the stock. Oppenheimer reaffirmed an "outperform" rating and set a $44.00 price objective (down from $48.00) on shares of Bicycle Therapeutics in a research report on Monday, August 11th. JMP Securities reduced their target price on shares of Bicycle Therapeutics from $22.00 to $10.00 and set a "market outperform" rating for the company in a research note on Tuesday. Barclays reduced their target price on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 target price on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. Finally, B. Riley reduced their target price on shares of Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $22.22.

Bicycle Therapeutics Price Performance

BCYC traded up $0.06 on Wednesday, reaching $7.44. 259,271 shares of the company traded hands, compared to its average volume of 307,205. The stock's 50 day moving average price is $7.85 and its 200-day moving average price is $8.80. Bicycle Therapeutics has a 52-week low of $6.10 and a 52-week high of $28.67. The company has a market cap of $515.22 million, a price-to-earnings ratio of -2.12 and a beta of 1.44.

Hedge Funds Weigh In On Bicycle Therapeutics

Institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. raised its position in shares of Bicycle Therapeutics by 55.3% in the first quarter. Principal Financial Group Inc. now owns 631,260 shares of the company's stock valued at $5,359,000 after purchasing an additional 224,790 shares during the period. Baker BROS. Advisors LP increased its position in Bicycle Therapeutics by 15.8% during the fourth quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company's stock worth $152,395,000 after acquiring an additional 1,485,397 shares during the period. Exchange Traded Concepts LLC increased its position in Bicycle Therapeutics by 90.3% during the first quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company's stock worth $108,000 after acquiring an additional 6,057 shares during the period. Fcpm Iii Services B.V. increased its position in Bicycle Therapeutics by 47.5% during the fourth quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company's stock worth $48,333,000 after acquiring an additional 1,112,369 shares during the period. Finally, Nan Fung Group Holdings Ltd increased its position in Bicycle Therapeutics by 118.3% during the fourth quarter. Nan Fung Group Holdings Ltd now owns 68,943 shares of the company's stock worth $965,000 after acquiring an additional 37,358 shares during the period. Institutional investors own 86.15% of the company's stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.